Harvest Fund Management Co. Ltd Acquires 1,653 Shares of IDEXX Laboratories, Inc. $IDXX

Harvest Fund Management Co. Ltd raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 26.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 7,815 shares of the company’s stock after buying an additional 1,653 shares during the quarter. Harvest Fund Management Co. Ltd’s holdings in IDEXX Laboratories were worth $4,990,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in IDXX. EverSource Wealth Advisors LLC raised its holdings in shares of IDEXX Laboratories by 2.5% during the third quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock worth $397,000 after acquiring an additional 15 shares during the period. Clearstead Trust LLC raised its stake in IDEXX Laboratories by 1.1% in the 2nd quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock valued at $813,000 after acquiring an additional 16 shares during the period. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of IDEXX Laboratories by 4.4% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock worth $243,000 after acquiring an additional 16 shares during the period. Moss Adams Wealth Advisors LLC boosted its position in shares of IDEXX Laboratories by 3.3% in the third quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock valued at $337,000 after acquiring an additional 17 shares during the period. Finally, Private Trust Co. NA grew its position in IDEXX Laboratories by 9.4% during the third quarter. Private Trust Co. NA now owns 209 shares of the company’s stock worth $134,000 after buying an additional 18 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 2,693 shares of the company’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $661.54, for a total value of $1,781,527.22. Following the completion of the sale, the executive vice president owned 19,899 shares in the company, valued at $13,163,984.46. This represents a 11.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Michael G. Erickson sold 5,371 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total value of $3,369,657.98. Following the sale, the executive vice president directly owned 12,693 shares in the company, valued at approximately $7,963,334.34. This represents a 29.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 45,957 shares of company stock worth $29,862,109. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Trading Up 0.5%

IDXX opened at $573.82 on Friday. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98. The stock has a market cap of $45.69 billion, a PE ratio of 43.90, a PEG ratio of 3.47 and a beta of 1.66. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The business has a 50 day moving average of $658.17 and a 200-day moving average of $666.52.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The business had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter last year, the company posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on IDXX shares. Wall Street Zen downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Barclays decreased their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. Piper Sandler lowered their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. Finally, UBS Group dropped their price objective on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research note on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $783.33.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.